Crinetics Pharmaceuticals, Inc. (CRNX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

Crinetics Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

Crinetics Pharmaceuticals, Inc. (CRNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $37.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2024-02-28

• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-03-31 was $8.70M, a 117.50% increase year-over-year.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-03-31 was $4.00M.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $37.00M, a 60.87% increase from fiscal 2022.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $23.00M, a 41.10% increase from fiscal 2021.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $16.30M, a 64.65% increase from fiscal 2020.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $9.90M.